Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
PACB Pacific Biosciences of California
11.330-0.250-2.16%
Close
02/06 16:00 ET
11.3300.0000.00%
Pre Mkt Price 02/07 04:07 ET
High
11.570
Open
11.320
Turnover
30.45M
Low
11.150
Pre Close
11.580
Volume
2.69M
Pre-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Judge Releases Decision Approving Meta’s Virtual-Reality Deal
The unsealed ruling lays out the FTC’s loss of its bid to block the Facebook parent company’s acquisition.4 min read
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives Average Rating of "Hold" From Analysts
Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Rating) has earned an average recommendation of "Hold" from the eight research firms that are presently covering the company, Marketbeat Ra
Pacific Biosciences of California (NASDAQ:PACB) Coverage Initiated at UBS Group
Stock analysts at UBS Group started coverage on shares of Pacific Biosciences of California (NASDAQ:PACB – Get Rating) in a research report issued to clients and investors on Thursday, The Fly report
Analyzing Standard BioTools (NASDAQ:LAB) & Pacific Biosciences of California (NASDAQ:PACB)
Standard BioTools (NASDAQ:LAB – Get Rating) and Pacific Biosciences of California (NASDAQ:PACB – Get Rating) are both medical companies, but which is the superior business? We will compare the two bu
PacBio to Report Fourth Quarter and Full Year 2022 Financial Results on February 16, 2023
MENLO PARK, Calif., Feb. 2, 2023 /PRNewswire/ -- PacBio (NASDAQ:PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year 2022 financial results on Thursday,
UBS Initiates Coverage on Pacific Biosciences of California With Neutral Rating, $13 Price Target
09:01 AM EST, 02/02/2023 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
Pacific Biosciences Initiated With a Neutral at UBS
Raymond James & Associates Purchases 1,365 Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Raymond James & Associates lifted its holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Rating) by 1.5% in the 3rd quarter, according to its most recent Form 13F filing with the
Pacific Biosciences of California (NASDAQ:PACB) Sees Large Volume Increase
Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Rating) saw an uptick in trading volume on Wednesday . 3,439,633 shares were traded during trading, a decline of 13% from the pre
Livestream the NFL on AFN Now!
The Defense Media Activity (DMA) and the American Forces Network (AFN) invite audiences to watch the NFL Conference Championships games and Super Bowl XVII on its new video on demand and livestreaming app, AFN Now. A little over two months after the worldwide launch of AFN Now, and following recent successful tests of the livestreaming function, forces and families living overseas now have free access to live professional sports. The network plans to livestream both NFC and AFC championship games this Sunday, Feb. 29, followed by the Super Bowl on Feb. 12. DMA Director Hal Pittman said, “DMA is working hard to provide our worldwide audiences with the very best entertainment, news, and sports...
Company Overview
More
Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: North America, Europe, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.
CEO： Mr. Christian O. Henry
Market： NASDAQ
Listing Date： 10/27/2010
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet